ArticleFrontiers in pharmacology2026
Gastrodin alleviates cardiomyocyte senescence by regulating autophagy through the AMPK/mTOR/4EBP1 pathway.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate whether Gastrodin (Gas) attenuates doxorubicin (Dox)-induced cardiomyocyte senescence and apoptosis by regulating the AMPK/mTOR/4EBP1 signaling pathway and autophagy-related processes. Methods: A Dox-induced senescence model was established in H9c2 cardiomyocytes, and different concentrations of Gas (0.5 mM and 1 mM) were used for intervention. Senescence phenotypes were evaluated using SA-β-gal staining and senescence-associated proteins (P16, P21, and P53). Furthermore, the autophagy inhibitor 3-MA and the AMPK inhibitor Compound C (CC) were applied. Combined with Western blotting, Annexin V/PI flow cytometry, and immunofluorescence techniques, the expression levels of senescence-related proteins, autophagy-related markers (LC3-II/I, Beclin-1, and p62), and the phosphorylation levels of key proteins in the AMPK/mTOR/4EBP1 signaling pathway were analyzed to explore the potential mechanism of Gas. Results: Compared with the Dox model group, Gas intervention dose-dependently reduced the percentage of SA-β-gal-positive cells, downregulated the protein expression levels of P16, P21, P53, and γ-H2AX, and significantly inhibited apoptosis. Mechanistically, Gas treatment partially ameliorated the abnormalities in autophagy-related markers induced by Dox, as evidenced by increased expression of LC3 and Beclin-1 and decreased accumulation of p62, and this ameliorative effect was partially attenuated by 3-MA. Further signaling pathway analysis demonstrated that Gas significantly increased the p-AMPK/AMPK ratio while decreasing the p-mTOR/mTOR and p-4EBP1/4EBP1 ratios. After AMPK inhibition with CC, the activation effect of Gas on autophagy and its protective effects against senescence and apoptosis were both attenuated. Conclusion: These findings indicate that Gas alleviates Dox-induced cardiomyocyte senescence and apoptosis, and its protective effects may be associated with regulation of the AMPK/mTOR/4EBP1 signaling pathway and improvement of autophagy-related processes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.